Blockchain Registration Transaction Record

Axim Biotech Seeks FDA CLIA Waiver for Revolutionary Dry Eye Test

Axim Biotechnologies files for FDA CLIA Waiver for TearScan Lf, aiming to revolutionize Dry Eye Disease diagnosis with point-of-care testing.

This development is crucial for millions suffering from Dry Eye Disease, particularly Aqueous Deficient Dry Eye, as it promises a more accurate and accessible diagnostic tool. By enabling point-of-care testing without the need for complex lab infrastructure, Axim's TearScan Lf test could significantly improve patient outcomes by facilitating timely and appropriate treatment. Furthermore, the potential CLIA waiver represents a leap forward in making advanced diagnostic technologies more widely available, underscoring the importance of innovation in healthcare accessibility.